• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

    3/22/24 6:14:00 PM ET
    $BEAM
    $DASH
    $LYFT
    $AVEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    EDP Services
    Technology
    Get the next $BEAM alert in real time by email

    The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston. The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors.

    The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI.

    Keynote speakers include:

    • Steve Kraus, Partner at Bessemer Venture Partners and world-renowned healthcare investor. He invested in Sirtris Pharmaceuticals (NASDAQ:SIRT); Affymax (NASDAQ:AFFY); Aveo (NASDAQ:AVEO); Alnara, acquired by Eli Lilly; and many more.
    • John Evans, CEO of Beam Therapeutics (NASDAQ:BEAM), leading biotechnology company in gene therapies with a market capitalization of $2.85 billion.
      • Fireside chat with Steve Knight, President and Managing Partner of F-Prime Capital, top VC firm in healthcare and technology with $2+ billion AUM.
    • Tim Westergren, Founder and Former CEO of Pandora (NYSE:P), the music streaming service with a market capitalization of over $100 billion. He most recently founded HelloCreator, an AI-based application to help creators navigate their careers.
    • Earl Jones, Partner at DCVC, deep tech VC firm with over $2.6 billion AUM, and Alex Rappaport, Founder and CEO of ZwitterCo, a company that develops membranes that reuses the world's toughest wastewaters.

    Advanced Track session speakers feature:

    • Nick Sinai, Senior Advisor at Insight Partners, former White House U.S. Deputy Chief Technology Officer, and former presidential cabinet member under Obama.
    • James Currier, Founder of NFX, a $1.6B venture capital firm focused on network effect businesses. He invested in Doordash (NASDAQ:DASH), Lyft (NASDAQ:LYFT), Poshmark (MCAP: $1.42B), and more.
    • Bryce Youngren, Managing Partner at Polaris Growth Fund, a dedicated growth buyout firm with over $5.5 billion in assets under management.

    "For this year's Entrepreneurship Summit, we are excited to build off of the momentum of last year's leadership and take it to new heights. We're looking forward to gathering the next generation of entrepreneurs under one roof for a full day of community building," said Nick Apostolicas, President of VCG.

    VCG gratefully acknowledges everyone who made this extraordinary event possible. Special thanks to our PLATINUM SPONSOR, DCVC; our GOLD SPONSOR, Graphene Ventures; our SILVER SPONSORS, F-Prime Capital, Third Rock Ventures, Lemann Program on Creativity and Entrepreneurship (LPCE), and Forum Ventures; and our BRONZE SPONSORS, Insight Partners, Blumberg Capital, Clearvision Ventures, Xfund, Octonic VR, senhasegura, WakeCap Technologies, and Boston College High School Jack Shields Center for Innovation.

    To purchase summit tickets, visit harvardvcg2024entrepreneurshipsummit.eventbrite.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240322999918/en/

    Get the next $BEAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAM
    $DASH
    $LYFT
    $AVEO

    CompanyDatePrice TargetRatingAnalyst
    Beam Therapeutics Inc.
    $BEAM
    2/20/2026$74.00Buy
    Canaccord Genuity
    DoorDash Inc.
    $DASH
    1/14/2026$280.00Outperform
    BNP Paribas Exane
    Lyft Inc.
    $LYFT
    12/19/2025$16.00Neutral → Underperform
    Wedbush
    Lyft Inc.
    $LYFT
    12/3/2025$20.00Sell → Neutral
    Arete
    DoorDash Inc.
    $DASH
    11/19/2025$260.00Hold → Buy
    Jefferies
    DoorDash Inc.
    $DASH
    11/13/2025$260.00Neutral → Outperform
    Wedbush
    DoorDash Inc.
    $DASH
    10/27/2025$315.00Buy
    Goldman
    DoorDash Inc.
    $DASH
    10/24/2025$272.00Equal Weight
    Barclays
    More analyst ratings

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

    Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31 Patients with SCD Demonstrated Deep Resolution of Red Blood Cell Dysfunction and Reduced Time in Hospital Driven by a Median of One Cell Collection Cycle and Rapid Engraftment U.S. Biologics License Application (BLA) Submission for risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the publication of data from

    4/1/26 5:12:19 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

    Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up Corrected M-AAT Comprised 94% of Total AAT with a Concomitant 84% Reduction in Mutant Z-AAT Following BEAM-302 60 mg Treatment Post-treatment Inducibility of AAT Observed During Respiratory Infection with a Patient Reaching ~30 µM Total AAT, Retaining 95% M-AAT Composition Well-tolerated Safety Profile Observed with Single Doses of BEAM-302 up to 75 mg; Safety Consistent Across Single-dose Part A and Part B Cohorts 60 mg Selected as Optimal Biological Dose, Supported by Strong Safety and E

    3/25/26 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gas Price Relief For Dashers

      Today, DoorDash (NASDAQ:DASH) is launching an emergency relief program to help ease the impact of rising prices at the pump for Dashers and keep more money in their wallets. The program includes 10% cash back on gas for U.S. Dashers using the DoorDash Crimson card and weekly relief payments for Dashers who drive 125 miles or more while dashing. Dashers who qualify for both could save between $1.40 to $1.90 per gallon* based on miles driven while actively completing deliveries in a week. The program will run until April 26, 2026. "Rising gas prices have a real impact on Dashers, especially those who are delivering the most. This program is about giving Dashers real savings at the p

    3/23/26 9:00:00 AM ET
    $DASH
    EDP Services
    Technology

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Beam Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Beam Therapeutics with a rating of Buy and set a new price target of $74.00

    2/20/26 8:23:45 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BNP Paribas Exane initiated coverage on DoorDash with a new price target

    BNP Paribas Exane initiated coverage of DoorDash with a rating of Outperform and set a new price target of $280.00

    1/14/26 8:40:46 AM ET
    $DASH
    EDP Services
    Technology

    Lyft downgraded by Wedbush with a new price target

    Wedbush downgraded Lyft from Neutral to Underperform and set a new price target of $16.00

    12/19/25 8:45:08 AM ET
    $LYFT
    Real Estate

    $BEAM
    $DASH
    $LYFT
    $AVEO
    SEC Filings

    View All

    SEC Form PRE 14A filed by Lyft Inc.

    PRE 14A - Lyft, Inc. (0001759509) (Filer)

    3/31/26 4:06:45 PM ET
    $LYFT
    Real Estate

    Amendment: SEC Form SCHEDULE 13G/A filed by Lyft Inc.

    SCHEDULE 13G/A - Lyft, Inc. (0001759509) (Subject)

    3/27/26 10:33:44 AM ET
    $LYFT
    Real Estate

    Amendment: SEC Form SCHEDULE 13G/A filed by DoorDash Inc.

    SCHEDULE 13G/A - DoorDash, Inc. (0001792789) (Subject)

    3/26/26 6:03:32 PM ET
    $DASH
    EDP Services
    Technology

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bellon Christine

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    4/2/26 5:27:06 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Cavanagh Bethany J

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    4/2/26 5:22:20 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Simon Amy

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    4/2/26 5:16:47 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Risher John David bought $100,179 worth of shares (7,490 units at $13.38), increasing direct ownership by 0.07% to 11,481,792 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/18/26 4:10:21 PM ET
    $LYFT
    Real Estate

    Chief Executive Officer Risher John David bought $99,617 worth of shares (5,030 units at $19.80), increasing direct ownership by 0.04% to 11,802,296 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    12/11/25 8:53:23 PM ET
    $LYFT
    Real Estate

    Director Lin Alfred bought $100,277,150 worth of shares (514,047 units at $195.07) (SEC Form 4)

    4 - DoorDash, Inc. (0001792789) (Issuer)

    11/28/25 7:02:02 PM ET
    $DASH
    EDP Services
    Technology

    $BEAM
    $DASH
    $LYFT
    $AVEO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FOTIVDA issued to AVEO PHARMACEUTICALS INC

    Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB HYDROCHLORIDE has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

    3/29/21 5:44:34 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FOTIVDA

    Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

    3/10/21 2:49:22 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Milan Kovac Joins DoorDash Board of Directors

    DoorDash, Inc. (NASDAQ:DASH) announced today that Milan Kovac, former Vice President of Optimus Robotics and Autopilot at Tesla, has been appointed to the company's Board of Directors, effective January 16, 2026. Tony Xu, co-founder and CEO of DoorDash, Inc., said, "Milan has spent his career building and scaling ambitious engineering programs at the intersection of AI, autonomy, and robotics. He brings a rare combination of technical depth and operational leadership. That experience will be invaluable as we continue to build products and infrastructure that help local businesses grow, give consumers access to more of their communities, and create new ways for people to earn. I'm excited

    1/20/26 4:05:00 PM ET
    $DASH
    EDP Services
    Technology

    TKO and DoorDash Announce Official Partnership Across WWE® and UFC®

    DoorDash Named Official On-Demand Delivery Partner of WWE and UFC DoorDash to Deliver First-of-its-Kind Integrations and Fan Engagement Opportunities with WWE Superstars and UFC Athletes TKO Group Holdings, Inc. (NYSE:TKO) and DoorDash (NASDAQ:DASH) today announced an official partnership that will connect fans to custom integrations and experiences across WWE, the global leader in sports entertainment, and UFC, the world's premier mixed martial arts organization. DoorDash will have a prominent presence across WWE's and UFC's most high-profile moments and platforms, including live events and broadcasts, and will also leverage the massive presence WWE has across social media and digita

    11/20/25 8:00:00 AM ET
    $DASH
    $TKO
    EDP Services
    Technology
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Financials

    Live finance-specific insights

    View All

    Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

    Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up Corrected M-AAT Comprised 94% of Total AAT with a Concomitant 84% Reduction in Mutant Z-AAT Following BEAM-302 60 mg Treatment Post-treatment Inducibility of AAT Observed During Respiratory Infection with a Patient Reaching ~30 µM Total AAT, Retaining 95% M-AAT Composition Well-tolerated Safety Profile Observed with Single Doses of BEAM-302 up to 75 mg; Safety Consistent Across Single-dose Part A and Part B Cohorts 60 mg Selected as Optimal Biological Dose, Supported by Strong Safety and E

    3/25/26 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

    New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Expected Cash Runway Now into Mid-2029 Through Execution of Key Clinical, Regulatory and Commercial Milestones Beam to Host

    2/24/26 7:01:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DoorDash Releases Fourth Quarter and Full Year 2025 Financial Results

    DoorDash, Inc. (NASDAQ:DASH) today announced its financial results for the quarter and fiscal year ended December 31, 2025. In addition to our financial results below, our annual letter to shareholders is available on the DoorDash investor relations website at http://ir.doordash.com. In 2025, we accelerated growth in our U.S. restaurant category, expanded consumer affordability through record DashPass signups, increased consumer retention and order frequency in our grocery and retail categories by improving selection and quality, increased merchant value by launching new services such as reservations for restaurants and Smart Campaigns for ads, and drove strong organic growth internationa

    2/18/26 4:05:00 PM ET
    $DASH
    EDP Services
    Technology

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lyft Inc.

    SC 13G/A - Lyft, Inc. (0001759509) (Subject)

    12/4/24 2:38:58 PM ET
    $LYFT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Lyft Inc.

    SC 13G/A - Lyft, Inc. (0001759509) (Subject)

    11/12/24 10:32:11 AM ET
    $LYFT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

    SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    11/12/24 9:50:15 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care